-
Conformation-Guided uPAR·uPA Inhibitor Discovery
2026-09-20
Khanna and colleagues used molecular-dynamics-derived uPAR conformations to identify IPR-456, a small molecule that disrupts the otherwise difficult uPAR·uPA protein-protein interaction. Binding, competition, derivative analysis, and breast-cancer cell assays connected computational discovery with reduced uPA binding and cancer-cell invasion, while also revealing selectivity among related cell behaviors.
-
Adipose-Neural Signaling in Cardiac Arrhythmia
2026-09-19
Fan et al. developed a stem cell-based coculture model showing how epicardial adipose tissue can communicate with sympathetic neurons and cardiomyocytes through a leptin–NPY/Y1R pathway. The study combines mechanistic perturbation with observations from atrial fibrillation patients, identifying NCX and CaMKII as downstream contributors and potential intervention points.
-
BMS 309403 Workflows for FABP4 Research
2026-09-18
BMS 309403 provides a focused way to test how FABP4 connects lipid trafficking with macrophage inflammation, foam-cell formation, and metabolic dysfunction. This practical guide covers assay design, mechanism-resolving controls, formulation, and troubleshooting for cardiovascular and metabolic disease models.
-
NHE1, Olfr2, and Octanal-Driven Atherosclerosis
2026-09-18
This Scientific Reports study identifies macrophage NHE1 as a downstream effector of octanal–Olfr2 signaling in atherosclerosis. Using ApoE−/− mice and RAW264.7 macrophages, the authors connect calcium-dependent oxidative stress and NLRP3-associated inflammation with foam-cell formation and plaque progression, providing a mechanistic basis for studying NHE1 as a potential intervention point.
-
Annexin V-PE Apoptosis Detection Kit Workflow
2026-09-17
Turn phosphatidylserine exposure into a rapid, live-cell readout for cytotoxicity studies, immune-cell profiling, and pathway experiments. This workflow shows how to pair Annexin V-PE staining with flow cytometry or microscopy while avoiding common interpretation and sample-preparation errors.
-
FPR2/ALX, Microglia, and Autoimmune Astrocytopathy
2026-09-17
The reference study identifies FPR2/ALX stimulation with Quin-C1 as a strategy to reduce AQP4-IgG- and complement-associated astrocytopathy in mice. Its depletion and kinase-inhibition experiments connect the protective phenotype to microglia, natural killer cells, and SYK-AKT signaling, while also highlighting the limits of translating a preclinical immune-modulation study to human NMOSD.
-
PML–HIF1AN Signaling in BMSC Osteogenesis
2026-09-16
The reference study identifies PML as a positive regulator of bone marrow mesenchymal stem cell osteogenic differentiation through HIF1AN ubiquitination, HIF1α–SOD3 transcriptional control, and PI3K/AKT signaling. Its combined genetic, biochemical, transcriptional, and pharmacological experiments provide a mechanistic framework for interpreting how PML may influence osteoporosis-related bone formation.
-
PERK Loss and Ferroptosis in Colorectal Cancer
2026-09-16
The reference study identifies PERK as a negative regulator of ferroptosis in colorectal cancer through its control of the ATF4–SLC7A11 axis. By combining cellular, in vivo, transcriptomic, and patient-sample analyses, it shows that PERK loss lowers SLC7A11, increases lipid peroxidation, and restricts tumor growth.
-
RIPA Lysis Buffer (Medium) for EV Signaling
2026-09-15
Translate extracellular-vesicle stimulation into pathway-ready lysates with a balanced detergent system and built-in inhibitor support. This practical guide shows where RIPA buffer strengthens Western blot and tissue workflows, and where detergent exposure requires optimization for immunoprecipitation and functional assays.
-
Cy5 NHS ester(Et): Practical Labeling Guide
2026-09-15
Cy5 NHS ester(Et) is a water-soluble fluorescent dye reagent for covalently labeling primary amines in proteins, peptides, and other biomolecules. It is suited to immediate-use protein fluorescent labeling, immunofluorescence staining, flow cytometry, and fluorescence microscopy workflows, but ethanol-based dissolution and long-term storage of prepared solutions should be avoided.
-
Minocycline HCl in Translational EV Research
2026-09-14
Minocycline HCl is more than a semisynthetic tetracycline antibiotic: it is a mechanistically useful perturbation tool for connecting inflammation, microglial activity, neuroprotection, and apoptosis with scalable extracellular-vesicle research. This article examines how to deploy minocycline hydrochloride rigorously alongside emerging EV manufacturing platforms while separating established evidence from forward-looking hypotheses.
-
BIBP 3226: A Causal Assay Guide for NPY/Y1R
2026-09-14
BIBP 3226 trifluoroacetate is a non-peptide antagonist for dissecting NPY Y1 and NPFF signaling. This guide moves beyond pathway description to show how the compound can strengthen causal assay design in cardiovascular, anxiety, and analgesia research.
-
LMO2–LDB1 Signaling in Acute Myeloid Leukemia
2026-09-13
The 2023 Cell Death and Disease study identifies an LMO2/LDB1 protein complex as a functional driver of leukemia-cell maintenance, extending LMO2 biology beyond its established roles in hematopoiesis and T-cell leukemia. Through perturbation experiments, protein interaction analysis, transcriptomics, ChIP-seq, and in vivo validation, the authors link LDB1 to apoptosis-associated regulation and show that increased LMO2 can partially compensate for LDB1 loss.
-
HyperScript™ Reverse Transcriptase for qPCR
2026-09-12
Learn how HyperScript™ Reverse Transcriptase (SKU K1071) can support RNA to cDNA conversion when cell viability, proliferation, and cytotoxicity studies generate low-abundance or structurally complex transcripts. This scenario-based guide connects product specifications with practical controls, protocol decisions, and evidence-linked interpretation.
-
Potassium Iodide in Translational Research
2026-09-11
Potassium Iodide offers a simple, water-compatible iodide source for thyroid biology, radioactive iodine thyroid blocking assays, and formulation controls. This guide shows how to use KI alongside, rather than confuse it with, responsive immunotherapy workflows such as MMP-2-triggered liposomal delivery.